[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Merck & Co’s Stock: Analyst Estimates & Ratings

Merck & Co., Inc. (MRK) is one of the world's leading pharmaceutical giants, known for developing breakthrough medicines and vaccines that have transformed healthcare globally. Headquartered in Rahway, New Jersey, the company has built a strong presence across oncology, vaccines, infectious diseases, and animal health, with blockbuster products like Keytruda driving its growth. Backed by decades of scientific innovation and a robust research pipeline, Merck continues to play a pivotal role in advancing treatments for some of the world's most challenging diseases.

With a market capitalization of roughly $316.95 billion, Merck has been a standout performer on Wall Street. The pharmaceutical...

Fundamentals

See More
  • Market Capitalization, $K 317,569,984
  • Shares Outstanding, K 2,469,824
  • Annual Sales, $ 65,011 M
  • Annual Income, $ 18,254 M
  • EBIT $ 12,969 M
  • EBITDA $ 18,807 M
  • 60-Month Beta 0.19
  • Price/Sales 4.88
  • Price/Cash Flow 11.24
  • Price/Book 6.90

Options Overview Details

View History
  • Implied Volatility 27.15% (-1.00%)
  • Historical Volatility 26.22%
  • IV Percentile 18%
  • IV Rank 39.88%
  • IV High 35.42% on 04/27/26
  • IV Low 21.66% on 12/08/25
  • Expected Move (DTE 4) 2.85 (2.21%)
  • Put/Call Vol Ratio 0.46
  • Today's Volume 14,095
  • Volume Avg (30-Day) 21,555
  • Put/Call OI Ratio 0.77
  • Today's Open Interest 476,694
  • Open Int (30-Day) 439,289
  • Expected Range 125.73 to 131.43

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $2.29
  • Number of Estimates 5
  • High Estimate $2.41
  • Low Estimate $2.20
  • Prior Year $2.58
  • Growth Rate Est. (year over year) -11.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
120.16 +7.01%
on 07/14/26
135.05 -4.79%
on 07/28/26
-0.28 (-0.22%)
since 07/07/26
3-Month
110.94 +15.90%
on 05/15/26
135.05 -4.79%
on 07/28/26
+16.28 (+14.50%)
since 05/07/26
52-Week
77.58 +65.74%
on 09/25/25
135.05 -4.79%
on 07/28/26
+48.21 (+59.99%)
since 08/07/25

Most Recent Stories

More News
Merck & Co’s Stock: Analyst Estimates & Ratings

Merck has outperformed the broader market over the past year, and analysts remain optimistic about the stock.

XLV : 165.68 (+0.75%)
$SPX : 7,757.64 (+0.62%)
MRK : 128.58 (+0.16%)
U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season

EMA also accepts application for the same population for ENFLONSIA based on results from the Phase 3 SMART trial If approved, children under two years of age at increased...

MRK : 128.58 (+0.16%)
MRK Q2 Deep Dive: Oncology and New Launches Drive Growth Amid Margin Compression

MRK Q2 Deep Dive: Oncology and New Launches Drive Growth Amid Margin Compression

MRK : 128.58 (+0.16%)
Covered Call Screener Results for August 4th

Covered Call Screener Results for August 4th

TGT : 149.70 (+1.78%)
OXY : 55.91 (-0.23%)
SBUX : 105.58 (+0.40%)
MRK : 128.58 (+0.16%)
SCHW : 107.60 (-0.06%)
Merck (NYSE:MRK) Posts Better-Than-Expected Sales In Q2 CY2026

Merck (NYSE:MRK) Posts Better-Than-Expected Sales In Q2 CY2026

MRK : 128.58 (+0.16%)
Merck: Q2 Earnings Snapshot

Merck: Q2 Earnings Snapshot

MRK : 128.58 (+0.16%)
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline

Sales Growth Reflects Continued Strength in Oncology, Including Initial Uptake of KEYTRUDA QLEX, and Animal Health, Plus Contributions From Launches Such as WINREVAIR ...

MRK : 128.58 (+0.16%)
Option Volatility And Earnings Report For Aug 3 - 7

It is another big week on the earnings front with a lots of big name companies reporting. This week could make or break the market. This week we have SpaceX, Advanced Micro Devices, Palantir Technologies,...

MSTR : 100.01 (+3.26%)
NVDA : 223.96 (+2.27%)
ANET : 188.67 (-1.90%)
AAPL : 313.33 (+0.29%)
SNDK : 1,212.21 (-3.68%)
MRK : 128.58 (+0.16%)
MCD : 274.48 (-0.64%)
DIS : 104.91 (+0.22%)
SHOP : 151.57 (+2.80%)
TSLA : 328.58 (+2.83%)
SPCX : 133.11 (+15.83%)
CAT : 842.19 (-1.72%)
What To Expect From Merck’s (MRK) Q2 Earnings

What To Expect From Merck’s (MRK) Q2 Earnings

MRK : 128.58 (+0.16%)
Jobs Numbers Set for Release Next Week

Monday U.S. Economic Lookahead S&P final U.S. manufacturing PMI (July) ISM manufacturing ...

SONY : 23.46 (+1.56%)
SNDK : 1,212.21 (-3.68%)
COP : 117.61 (+0.73%)
NVO : 47.26 (+2.81%)
CAT : 842.19 (-1.72%)
MRK : 128.58 (+0.16%)
VRTX : 496.07 (+2.49%)
AMD : 483.36 (-1.21%)
LLY : 1,185.71 (-0.52%)
PH : 1,073.87 (+0.38%)
PLTR : 172.01 (+10.32%)
MAR : 353.91 (-1.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 131.40
2nd Resistance Point 130.07
1st Resistance Point 129.33
Last Price 128.58
1st Support Level 127.26
2nd Support Level 125.93
3rd Support Level 125.19

See More

52-Week High 135.05
Last Price 128.58
Fibonacci 61.8% 113.10
Fibonacci 50% 106.32
Fibonacci 38.2% 99.53
52-Week Low 77.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.